Iopimax (Apraclonidine)

Apraclonidine selectively stimulates alpha‑2 receptors in the ciliary body, decreasing aqueous humor production and increasing uveoscleral outflow. This dual action results in a net reduction of intraocular pressure.

The dosing regimen for Iopimax is determined by the prescribing ophthalmologist based on the patient’s condition, severity, and response to therapy. The prescriber will specify the number of drops and frequency.

Safety of apraclonidine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and after consultation with a healthcare professional.

To request Iopimax, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iopimax (apraclonidine) is a selective alpha‑2 agonist, whereas many other glaucoma drops are beta‑blockers, prostaglandin analogues or carbonic anhydrase inhibitors. Apraclonidine primarily reduces aqueous production and enhances outflow, offering an alternative mechanism that can be combined with other classes for additive pressure control.

Store Iopimax below 25 °C in its original packaging, protecting it from light and moisture. Do not freeze the product, and keep the container tightly closed when not in use.

Iopimax is applied topically as an eye drop. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s) according to the ophthalmologist’s instructions, typically avoiding contact with the eyelid or lashes.

Serious adverse events, though rare, include severe ocular inflammation, allergic contact dermatitis, persistent hypotony, and systemic hypotension or bradycardia. Patients should seek immediate medical attention if they experience sudden vision loss, severe eye pain, or systemic symptoms such as dizziness.

Iopimax should be avoided in patients with known hypersensitivity to apraclonidine or any component of the formulation, in those with severe cardiovascular instability, and in individuals where the risk of further lowering intraocular pressure outweighs the benefit, such as eyes with already low pressure.